Evidence map›Paper›PMID 39415140›Full record

ArticleRespiratory research2024

A genome-wide association study of adults with community-acquired pneumonia.

Eva Suarez-Pajes, Itahisa Marcelino-Rodriguez, Elisa Hernández Brito, Silvia Gonzalez-Barbuzano, Melody Ramirez-Falcon, Eva Tosco-Herrera, Luis A Rubio-Rodríguez, María Luisa Briones, Olga Rajas, Luis Borderías and 12 more

Abstract read
In one paragraph

Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Eva Suarez-Pajes *Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias (IISC), Santa Cruz de Tenerife, Spain.
Itahisa Marcelino-Rodriguez *Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias (IISC), Santa Cruz de Tenerife, Spain.
Elisa Hernández Brito *Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Silvia Gonzalez-BarbuzanoResearch Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias (IISC), Santa Cruz de Tenerife, Spain.
Melody Ramirez-FalconResearch Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias (IISC), Santa Cruz de Tenerife, Spain.
Eva Tosco-HerreraResearch Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias (IISC), Santa Cruz de Tenerife, Spain.
Luis A Rubio-RodríguezGenomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain.
María Luisa BrionesDepartment of Respiratory Diseases, Hospital Clínico y Universitario de Valencia, Valencia, Spain.
Olga RajasDepartment of Respiratory Diseases, Hospital Universitario de la Princesa, Madrid, Spain.
Luis BorderíasDepartment of Respiratory Diseases, Hospital Universitario San Jorge, Huesca, Spain.
Jose FerreresIntensive Care Unit, Hospital Clínico de Valencia, Valencia, Spain.
Antoni PayerasDepartment of Internal Medicine, Hospital Son Llatzer, Palma de Mallorca, Spain.
Leonardo LorenteIntensive Care Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain.
Javier AspaDepartment of Respiratory Diseases, Hospital Universitario de la Princesa, Madrid, Spain.
Jose M Lorenzo SalazarGenomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain.
José Manuel Valencia-GallardoDepartment of Respiratory Diseases, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Nieves CarbonellIntensive Care Unit, Hospital Clínico de Valencia, Valencia, Spain.
Jorge L FreixinetInstituto Universitario de Investigaciones Biomédicas y Sanitarias, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Felipe Rodríguez de CastroDepartment of Respiratory Diseases, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Jordi Solé ViolánDepartment of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain.
Carlos Flores *Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias (IISC), Santa Cruz de Tenerife, Spain. cflores@ull.edu.es.
Carlos Rodríguez-Gallego *Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain. jrodgal@gobiernodecanarias.org.

Funding

Agencia Canaria de Investigación, Innovación y Sociedad de la Información de la Consejería de Economía, Conocimiento y Empleo y por el Fondo Social Europeo (FSE) Programa Operativo Integrado de Canarias 2014-2020, Eje 3 Tema Prioritario 74 (85%) TESIS2021010046Agencia Canaria de Investigación, Innovación y Sociedad de la Información de la Consejería de Economía, Conocimiento y Empleo y por el Fondo Social Europeo (FSE) Programa Operativo Integrado de Canarias 2014-2020, Eje 3 Tema Prioritario 74 (85%) TESIS2022010042Cabildo Insular de Tenerife CGIEU0000219140Fundación Canaria Instituto de Investigación Sanitaria de Canarias PIFIISC19/43Grupo DISA OA18/017Instituto de Salud Carlos III PI13/01456Instituto de Salud Carlos III PI17/00610ITER OA17/008Ministerio de Ciencia e Innovación co-financed by the European Regional Development Funds (ERDF), "A way of making Europe" from the EU RTC-2017-6471-1; AEI/FEDER
6 · The paper itself

Abstract

backgroundCommunity-acquired pneumonia (CAP) is associated with high morbidity and hospitalization rate. In infectious diseases, host genetics plays a critical role in susceptibility and immune response, and the immune pathways involved are highly dependent on the microorganism and its route of infection. Here we aimed to identify genetic risk loci for CAP using a case-control genome-wide association study (GWAS).

methodsWe performed a GWAS on 3,765 Spanish individuals, including 257 adult patients hospitalized with CAP and 3,508 population controls. Pneumococcal CAP was documented in 30% of patients; the remaining 70% were selected among patients with unidentified microbiological etiology. We tested 7,6 million imputed genotypes using logistic regressions. UK Biobank GWAS of bacterial pneumonia were used for results validation. Subsequently, we prioritized genes and likely causal variants based on Bayesian fine mapping and functional evidence. Imputation and association of classical HLA alleles and amino acids were also conducted.

resultsSix independent sentinel variants reached the genome-wide significance (p < 5 × 10

conclusionsWe completed a GWAS of CAP and identified four novel risk loci involved in CAP susceptibility.

Indexed as

Community-Acquired InfectionsGenome-Wide Association StudyAdultAgedCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPneumoniaPolymorphism, Single NucleotideSpainGWASHost geneticsInborn errors of immunityPneumonia

Identifiers

PMID39415140
PMCPMC11484206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.